I want to finish my comments here where we started this call, which is with our drug development principles ... to what has been reported for dupilumab. Though as we have said, we believe the ...

Chief executive Paul Hudson said the move will be accompanied by measures to “optimise” Sanofi’s cost structure ... immunology blockbuster Dupixent (dupilumab), which grew by a third ...

Under the new structure, due to come into effect next ... immunology candidates including arthritis therapy sarilumab and dupilumab for asthma. Two key objectives for Sanofi under Brandicourt ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Each cell in your body relies on precise communication with other cells to function properly. At the center of this process are the molecular switches that turn communication signals in the body on ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

Engineers devised a way to deliver drugs such as contraceptives by injecting them as suspended crystals. Once under the skin, the crystals assemble into a drug depot that can last for months or years, ...

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was able to improve lichenification among patients aged 6 to 88 years with atopic dermatitis.

Dupilumab is safe and efficacious for the treatment of atopic dermatitis for 3 years among pediatric patients aged 6 months to 11 years.